Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-10-21
Schrödinger, Inc.
Schrödinger sells computational molecular discovery software to pharma, biotech, industrial, and academic customers while also monetizing collaborative and proprietary drug discovery programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From modeling suite to discovery system
The upside case rests on becoming a broader operating layer for molecular discovery, not on a single drug outcome. The stock can work if hosted delivery and AI modules convert scientific relevance into cleaner, larger, and stickier software revenue.

Analysis

Thesis
Over five years, Schrödinger can turn a respected modeling suite into a higher-value discovery workflow system: hosted delivery, AI modules, and program-level monetization should lift wallet share inside large pharma while collaborations add upside without requiring heavy capex.
Last Economy Alignment
Cheaper cognition expands the amount of molecular design work done in software, and Schrödinger owns validated scientific workflows. The cap is that value capture still leans on seat and contract economics, so AI can raise utility faster than price unless the company shifts toward program-level capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.3x (from 5 most recent analyses)
Reasoning
This is a credible 2x-type setup, not a moonshot. The core case is that hosted revenue recognition normalizes, software annual contract value compounds, and newer AI products move Schrödinger from expert-user software toward a broader discovery operating layer. I do not need major proprietary drug wins to make the case; I mainly need deeper account monetization, cleaner renewals, and modest collaboration upside.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not technological irrelevance; it is weak value capture. Schrödinger must prove that hosted delivery, Bunsen, and adjacent workflow tools convert into broader, less concentrated, and higher-quality software revenue before the market will pay a stronger multiple.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.40
They own trusted molecular-design software and a shared research workspace, so cheaper AI should push more discovery work onto their system. The risk is that AI cuts paid seat counts or shifts orchestration into customer-built tools before Schrödinger changes how it gets paid.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$25.86
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case